Dr. Sharyl Fyffe-Maricich, PhD
Senior Director and Head of Molecular Biology Research at Ultragenyx Pharmaceutical

Dr. Sharyl Fyffe-Maricich, received a BS degree from Queen’s University in Canada, and a PhD in Human and Molecular Genetics from Baylor College of Medicine. She completed her graduate training in the lab of Dr. Huda Zoghbi where she studied the contribution of specific neuronal subpopulations to the underlying biology of Rett Syndrome. Following her postdoctoral training at Case Western Reserve University in Cleveland, Sharyl joined the University of Pittsburgh School of Medicine faculty as a tenure track Assistant Professor of Pediatric Neurology. Her work was supported by the National Multiple Sclerosis Society and NIH R01 funding from the National Institute of Neurological Disorders and Stroke (NINDS). Sharyl joined Ultragenyx in 2016 as the Director of Molecular Biology where she leads a research team of scientists and associates who are focusing their efforts on the company’s preclinical neuroscience programs, including an AAV9 gene therapy for CDD. In addition to her role at Ultragenyx, Sharyl is currently serving as a scientific advisory board member for the PCH19 Epilepsy Alliance.